IMF-001

· ImmunoFrontier, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMF-001, covering 2015-03-10 to 2015-03-10. Get the full timeline:

Most recent: Clinical Trial Update: Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 [Phase 1]